JUV 161
Alternative Names: JUV-161Latest Information Update: 05 Jun 2024
Price :
$50 *
At a glance
- Originator Juvena Therapeutics
- Class Antirheumatics; Proteins; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Muscular dystrophies; Myotonic dystrophy
- Research Osteoarthritis
Most Recent Events
- 05 Jun 2024 Juvena Therapeutics announces intention to file an IND application with the US FDA in USA for Myotonic Dystrophy Type 1 (DM1), in the first half of 2024 (Juvena Therapeutics, June 2024)
- 23 Jan 2024 JUV 161 receives Orphan Drug status for Myotonic dystrophy in USA
- 23 Jan 2024 Pharmacodynamics data from preclinical studies in Myotonic dystrophies released by Juvena Therapeutics